Loss of TSC2 expression and, therefore, abnormally enhanced mTOR activity, have been associated with lung‐metastatic potential in breast cancer (Jiang et al, 2005; Nasr et al, 2013; Ruiz de Garibay et al, 2015; Mateo et al, 2017). Here, MTOR is linked to breast cancer.